20 "

: Simovil 20 Mg. ?  »
|
-

PER OS

Tablets

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simovil is indicated to: Reduce the risk of total mortality by reducing coronary death; Reduce the risk of non-fatal myocardial infarction; Reduce the risk for undergoing myocardial revascularization procedures; Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simovil is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simovil therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simovil is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia): Simovil is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia ( Fredrickson type III hyperlipidemia). Simovil is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).

127 52 26695 00

Merck Sharp & Dohme B.v, Holland

01/2013 - 01/2023

.
, .
.
/
Simvastatin 20 MG
Blister pvc/pe/pvdc/al 10 x TABLETS 24
Blister pvc/pe/pvdc/al 30 x TABLETS 24
Blister pvc/pe/pvdc/al 60 x TABLETS 24
Blister pvc/pe/pvdc/al 100 x TABLETS 24

*

*

 

.

 
" !
 

...
 »
530
-